GenSight Biologics to present new GS010 data at the 2019 Annual Meeting of the American Academy of Ophthalmology

Future is now: Leaders in Ocular Gene Therapy Meeting, San Francisco (CA)

GenSight Biologics reports sustained efficacy and safety at 96 weeks in RESCUE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

EURETINA 2019 Congress, Paris, France

2019 Annual Meeting ASRS, Chicago, IL (US)

GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule

GenSight Biologics announces presentation of results from the REVERSE Phase III trial of GS010 at the 14th meeting of the European Neuro-Ophthalmology Society (EUNOS)

14th Meeting of EUNOS, Porto, Portugal

2019 SOE Congress, European Society of Ophthalmology, Nice, France

Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude